Skip to main content
Premium Trial:

Request an Annual Quote

Ceres Nanosciences Raises $3M in Series A Funding

NEW YORK (GenomeWeb) – Ceres Nanosciences announced today it has closed on $3 million in Series A financing, part of what the company said was a larger $9 million Series A round.

The round was led by Concord, Massachusetts-based venture firm GreyBird Ventures, which has said it intends to provide a total of up to $5.5 million in funds over the next year.

The company said it intends to use the financing to further develop its Lyme disease diagnostic. The test uses Ceres' Nanotrap enrichment technology to detect Lyme antigens in patient urine at the early stages of the disease. Developed at George Mason University, the Nanotrap uses hydrogel particles to capture, preserve, and enrich target analytes, allowing for more sensitive detection of low abundance molecules.

"Ceres Nanosciences has solved a fundamental problem in precision medicine, concentrating the most interesting biomarkers of early stage disease that have a low natural abundance," GreyBird Cofounder Tom Miller said in a statement. "The Lyme disease test is just the first example."

Ceres also announced that Miller has recently joined its board of directors.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.